Member Info for KilkennyTed

@Levs the previous £5 spike was normal aim behaviour for this share at that time. Novacyt is a completely different proposition now and is still way undervalued imo. £5 might be some investors exit point but it will also be some investors entry point.

about to go into orbit. So many products and new projects on the horizon. All will help with a big re rate & give this company a fair valuation. Any talk of takeovers can wait till then.

Versalab class 44
Medical services; medical services namely blood, saliva, urine, tissue, hair and body fluid testing services; medical testing services in the field of epidemiology and genetics; DNA and RNA analyses for medical and scientific purposes; DNA and RNA screening for scientific and medical purposes; viral screening for scientific and medical purposes; medical and health services in connection with DNA and RNA; provision of medical record services online; collection, sampling and preservation of human blood, saliva, urine, tissue, hair and body fluids; medical testing for diagnostic and epidemiological purposes; medical testing for epidemiological purposes; interpretation of medical biology test results; bio-pathological information and advice relating to medical biology tests; infectious disease testing; medical testing services in relation to the diagnosis and treatment of disease; testing services for humans; provision of advice and information relating to testing services; consultancy in relation to medical testing services.

Versalab class 42
Scientific services and research and design relating thereto; diagnostic testing services; laboratory testing services; laboratory services for analytical testing; computer aided testing services; research and testing services in the fields of bacteriology and virology; research and testing services in the field of infectious diseases; development of methods namely establishment and carrying out of physical, chemical, physical-chemical, biochemical, biological, epidemiological, microbiological, molecular biological, immunological and biomolecular testing methods; DNA, RNA and virus analyses for scientific purposes; managing and providing scientific research information, analysis data and results from an online searchable database; consultancy in relation to diagnostic testing services.

DHSC requests companies to submit proposals for the production of 1.5m swab tests & 3m saliva tests per day.

https://www.thetimes.co.uk/edition/news/coronavirus-matt-han****-banks-on-saliva-tests-for-operation-moonshot-lift-off-56vv0r26x

Primer design recently submitted applications for 2 new trademarks. Promate and Versalab.
Promate same trademark class as previous products such as exisig.
Versalab is in a different trademark class. Looks more like a lab service than a product. Hmm?

https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003534431

Hi Kaeren if you have set a limit at 14 and there are enough buy orders on the way up yours will be taken out @14

It is huge news. Remember the impact when it was announced the French wouldn't reimburse because it was a single gene test & the slow slide to the £2 range. On the positive side it gave peeps who bought at the peak the chance to average down . Hopefully everyone's head is above water now and should be well rewarded in the coming weeks. Cheers all.

Still a few % short for the EGM but Mandy say's they are receiving forms every 30 seconds. So could be tight.

Was that Wilson?

633million to run a testing survey. Swabs & Blood samples
http://bidstats.uk/tenders/2020/W39/735641695

Nice find

Troublesome they sound like 2 of the team names on The Apprentice :)

Hi.
Long term holder but not a board member so don't know is the answer.

I posted the link earlier it should work
https://www.flipsnack.com/digitap/abc-19-rapid-test.html

Snap!!

There is an email address on form or you can send to
mandy.cowling@novacyt.com

You can email Mandy a copy of your Proxy Form & Proof of holding that will do it. I did yesterday & she confirmed all perfect.

Part of report published in June from Prof. Jo Martin . Primer Design rose to the occasion.
SARS-CoV-2 is not the only virus
SARS-CoV-2 PCR viral screening will need to be integrated into routine seasonal outbreak testing alongside influenza and other respiratory viruses, as well as gastrointestinal pathogen panels
for patients on admission and potentially during their stay in hospital. This may be through near-patient testing or testing in local laboratories. Both will need to be quality controlled by experienced laboratory professionals and require short turnaround times.
Improvements in the sensitivity and range of testing should also enable COVID-19 to be ruled out in appropriate clinical settings, ensuring that alternative diagnoses are sought rather than missed and enabling operational optimisation in healthcare settings. Work with diagnostic industry partners will be needed to develop these multiplexed assays at pace. Procurement pathways will also need to support this in a timely manner.
Ongoing monitoring of virus prevalence will be required, supported by improved data connectivity and simpler reporting for all surveillance purposes.

https://d3n8a8pro7vhmx.cloudfront.net/marchforchange/pages/376/attachments/original/1598542982/RCPath-COVID-19-testing-a-national-strategy.pdf?1598542982

It is borderline criminal. Investors piled into TT and price went up 40% only to come crashing down again.

Read this
https://www.sharebuyers.co.uk/shares/ttg-share-price-crashes-iabra-virolens-exposed-no-approvals/